Back to Stocks

SRRK

Scholar Rock Holding Corp
7 filings tracked
healthcarebiotechnologySMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Scholar Rock is strategically positioned for a high-conviction regulatory inflection point as it approaches the September 30, 2026, PDUFA date for apitegromab in spinal muscular atrophy (SMA).…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic narrative, Scholar Rock's financial trajectory reveals a concerning acceleration in cash burn. The company reported a net loss of $105.5 million for the first quarter of 2026, driven by a staggering 76.7% increase in general and administrative expenses.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every SRRK filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing portrays a company at a critical crossroads, balancing a promising clinical lead with an intensifying financial burn. The resubmission of the apitegromab BLA and the establishment of a September 2026 PDUFA date provide a concrete catalyst for investors, but the cost of preparing for this launch is substantial. The surge in G&A spending reflects management's confidence in approval, yet it simultaneously increases the penalty for any further regulatory delays. Ultimately, the investment thesis hinges on the binary outcome of the FDA's decision. A successful approval would validate the commercial infrastructure spend and unlock further funding tranches. Conversely, any further CRL or manufacturing hurdle would leave the company with an oversized, expensive corporate structure and a dwindling cash reserve. Investors must weigh the potential for a blockbuster launch in SMA and obesity against the reality of a highly levered balance sheet and a history of significant accumulated deficits.

Selected Quarter

Core Takeaway

Scholar Rock is aggressively spending to prepare for the launch of apitegromab, shifting from a research-heavy model to a commercial-ready organization while managing significant debt and regulatory hurdles.

Investor Lens

The trade-off is between the potential of a first-in-class myostatin inhibitor and the risk of a highly levered, pre-revenue company facing binary regulatory risk.

Watch Next

The September 30, 2026 PDUFA action date and any updates regarding the FDA's reinspection of the fill-finish facilities.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.02Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

G&A expenses surged 76.7% to $50.2 million as the company scales for commercial launch.

margin compression
80%
neutralMay 7

Raised $111.8 million through ATM equity sales and $200 million via a Blue Owl debt facility.

capital raise
60%
bullishMay 7

FDA accepted BLA resubmission for apitegromab with a PDUFA date of September 30, 2026.

regulatory action
70%
neutralMay 7

Terminated legacy Oxford loan and entered into a new $350 million capacity agreement with Blue Owl.

debt restructure
50%
bearishMay 7

G&A expenses surged 76.7% to $50.2 million as the company scales for commercial launch.

margin compression
80%
neutralMay 7

Raised $111.8 million through ATM equity sales and $200 million via a Blue Owl debt facility.

capital raise
60%
bullishMay 7

FDA accepted BLA resubmission for apitegromab with a PDUFA date of September 30, 2026.

regulatory action
70%
neutralMay 7

Terminated legacy Oxford loan and entered into a new $350 million capacity agreement with Blue Owl.

debt restructure
50%
bearishMay 7

G&A expenses surged 76.7% to $50.2 million as the company scales for commercial launch.

margin compression
80%
neutralMay 7

Raised $111.8 million through ATM equity sales and $200 million via a Blue Owl debt facility.

capital raise
60%
bullishMay 7

FDA accepted BLA resubmission for apitegromab with a PDUFA date of September 30, 2026.

regulatory action
70%
neutralMay 7

Terminated legacy Oxford loan and entered into a new $350 million capacity agreement with Blue Owl.

debt restructure
50%
bearishMay 7

G&A expenses surged 76.7% to $50.2 million as the company scales for commercial launch.

margin compression
80%
neutralMay 7

Raised $111.8 million through ATM equity sales and $200 million via a Blue Owl debt facility.

capital raise
60%
bullishMay 7

FDA accepted BLA resubmission for apitegromab with a PDUFA date of September 30, 2026.

regulatory action
70%
neutralMay 7

Terminated legacy Oxford loan and entered into a new $350 million capacity agreement with Blue Owl.

debt restructure
50%
bearishMay 7

G&A expenses surged 76.7% to $50.2 million as the company scales for commercial launch.

margin compression
80%
neutralMay 7

Raised $111.8 million through ATM equity sales and $200 million via a Blue Owl debt facility.

capital raise
60%
bullishMay 7

FDA accepted BLA resubmission for apitegromab with a PDUFA date of September 30, 2026.

regulatory action
70%
neutralMay 7

Terminated legacy Oxford loan and entered into a new $350 million capacity agreement with Blue Owl.

debt restructure
50%
bearishMay 7

G&A expenses surged 76.7% to $50.2 million as the company scales for commercial launch.

margin compression
80%
neutralMay 7

Raised $111.8 million through ATM equity sales and $200 million via a Blue Owl debt facility.

capital raise
60%
bullishMay 7

FDA accepted BLA resubmission for apitegromab with a PDUFA date of September 30, 2026.

regulatory action
70%
neutralMay 7

Terminated legacy Oxford loan and entered into a new $350 million capacity agreement with Blue Owl.

debt restructure
50%
bearishMay 7

G&A expenses surged 76.7% to $50.2 million as the company scales for commercial launch.

margin compression
80%
neutralMay 7

Raised $111.8 million through ATM equity sales and $200 million via a Blue Owl debt facility.

capital raise
60%
bullishMay 7

FDA accepted BLA resubmission for apitegromab with a PDUFA date of September 30, 2026.

regulatory action
70%
neutralMay 7

Terminated legacy Oxford loan and entered into a new $350 million capacity agreement with Blue Owl.

debt restructure
50%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing portrays a company at a critical crossroads, balancing a promising clinical lead with an intensifying financial burn. The resubmission of the apitegromab BLA and the establishment of a September 2026 PDUFA date provide a concrete catalyst for investors, but the cost of preparing for this launch is substantial. The surge in G&A spending reflects management's confidence in approval, yet it simultaneously increases the penalty for any further regulatory delays. Ultimately, the investment thesis hinges on the binary outcome of the FDA's decision. A successful approval would validate the commercial infrastructure spend and unlock further funding tranches. Conversely, any further CRL or manufacturing hurdle would leave the company with an oversized, expensive corporate structure and a dwindling cash reserve. Investors must weigh the potential for a blockbuster launch in SMA and obesity against the reality of a highly levered balance sheet and a history of significant accumulated deficits.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.